- Eight product approvals granted in 2020 with further 26 product submissions pending for approval across the fast-growing SEA region
Lotus Pharmaceutical Co., Ltd. (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795) today provided a business update for its commercial operation in South East Asia (SEA). After a very solid first quarter performance for the region, the Company has obtained a total of eight marketing approvals in the first six months of 2020. Lotus has also made another 26 product submissions pending for approval to further diversify and strengthen its product offering across the region.
Petar Vazharov, Chief Executive Officer of Lotus, commented:
Market backdrop Lotus has announced that they have successfully integrated their operations in South East Asia and obtained eight marketing approvals YTD’20. This is in addition to the assets Lotus has acquired which further captures the fastest growing market in the world. The Company has started to consolidate revenues from the SEA market, which includes Thailand, Vietnam, Singapore, Philippines, Malaysia, Indonesia, Myanmar, Sri Lanka, and Bangladesh, since this quarter 2020.